Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 t-haNK and Rituximab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT06334991Phase 1Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2024
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19t-haNK in non-Hodgkin lymphoma (NHL), sponsored by ImmunityBio, Inc. Primary endpoints: Overall safety evaluation at 30 days and Incidence of treatment-emergent AEs and serious AEs at 12 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
CD19t-haNK
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06334991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06334991.